Literature DB >> 22787225

Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice.

Florian Krammer1, Natalie Pica, Rong Hai, Gene S Tan, Peter Palese.   

Abstract

Previously, it has been shown that infection in humans with the pandemic swine influenza virus induces antibodies with specificity to the stalk domain of the viral hemagglutinin. Following the generation of these data, we sought to recapitulate these findings in the mouse model by sequential influenza virus infection. Mice that were inoculated with a seasonal influenza H1N1 virus followed by infection with a pandemic H1N1 strain produced higher antihemagglutinin stalk antibody titers than mice sequentially infected with drifted seasonal strains. In order to achieve antibody titers of comparable magnitude using sequential infection, mice had to be infected with 100- to 1,000-fold more of the drifted seasonal virus. The antistalk antibodies produced by these infections were influenza virus neutralizing, which illustrates the utility of the mouse model in which to study this interaction between virus and host.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787225      PMCID: PMC3457330          DOI: 10.1128/JVI.01336-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

2.  Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies.

Authors:  A Jungbauer; C Tauer; M Reiter; M Purtscher; E Wenisch; F Steindl; A Buchacher; H Katinger
Journal:  J Chromatogr       Date:  1989-08-04

3.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

4.  Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.

Authors:  John Steel; Anice C Lowen; Lindomar Pena; Matthew Angel; Alicia Solórzano; Randy Albrecht; Daniel R Perez; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  Simplified recombinational approach for influenza A virus reverse genetics.

Authors:  Shuai Wang; Qinfang Liu; Juan Pu; Yishan Li; Liya Keleta; Yu-Wen Hu; Jinhua Liu; Earl G Brown
Journal:  J Virol Methods       Date:  2008-05-05       Impact factor: 2.014

6.  Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Erin Petersen; Thomas M Moran; Peter Palese
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

7.  Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Authors:  John Steel; Anice C Lowen; Taia T Wang; Mark Yondola; Qinshan Gao; Kester Haye; Adolfo García-Sastre; Peter Palese
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

8.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

Review 9.  Why do influenza virus subtypes die out? A hypothesis.

Authors:  Peter Palese; Taia T Wang
Journal:  MBio       Date:  2011-08-30       Impact factor: 7.867

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  55 in total

1.  Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.

Authors:  Chi-Jene Chen; Megan E Ermler; Gene S Tan; Florian Krammer; Peter Palese; Rong Hai
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

2.  Universal influenza virus vaccines: need for clinical trials.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

3.  Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Authors:  Florian Krammer; Rong Hai; Mark Yondola; Gene S Tan; Victor H Leyva-Grado; Alex B Ryder; Matthew S Miller; John K Rose; Peter Palese; Adolfo García-Sastre; Randy A Albrecht
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 4.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

5.  Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.

Authors:  Wenqian He; Gene S Tan; Caitlin E Mullarkey; Amanda J Lee; Mannie Man Wai Lam; Florian Krammer; Carole Henry; Patrick C Wilson; Ali A Ashkar; Peter Palese; Matthew S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

6.  Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

Authors:  Florian Krammer; Natalie Pica; Rong Hai; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

7.  Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.

Authors:  James R R Whittle; Adam K Wheatley; Lan Wu; Daniel Lingwood; Masaru Kanekiyo; Steven S Ma; Sandeep R Narpala; Hadi M Yassine; Gregory M Frank; Jonathan W Yewdell; Julie E Ledgerwood; Chih-Jen Wei; Adrian B McDermott; Barney S Graham; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

8.  Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Authors:  Peter H Goff; Tomoko Hayashi; Wenqian He; Shiyin Yao; Howard B Cottam; Gene S Tan; Brian Crain; Florian Krammer; Karen Messer; Minya Pu; Dennis A Carson; Peter Palese; Maripat Corr
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

9.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

Review 10.  The prospects and challenges of universal vaccines for influenza.

Authors:  Kanta Subbarao; Yumiko Matsuoka
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.